Citigroup, Inc (NYSE: C) Downgrades Genzyme (NASDAQ: GENZ), Boosts Price Target - American Banking News PDF Print
American Banking NewsThe Company's product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and immune ...Citigroup Downgrades Genzyme (GENZ) to Hold StreetInsider.com (subscription)Hostile Bid in the Works for Genzyme Corp (NASDAQ: GENZ), Citigroup, Inc (NYSE

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.